Longbio Pharma (Suzhou) Co (HKSE:01779) EBIT: HK$ Mil (TTM As of Dec. 2025)


HKSE:01779 Longbio Pharma (Suzhou) Co Ltd HKSE:01779
10 GF Score
Price HK$150.00
View Full Analysis

What is Longbio Pharma (Suzhou) Co EBIT?

Longbio Pharma (Suzhou) Co HKSE:01779 -4.58% 10 EBIT is HK$ Mil as of Dec. 2025. GuruFocus rates HKSE:01779 with a GF Score™ of 10/100.

Longbio Pharma (Suzhou) Co's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was HK$-175.35 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Longbio Pharma (Suzhou) Co's annualized ROC % for the quarter that ended in Dec. 2025 was -161.31%. Longbio Pharma (Suzhou) Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -997.74%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Longbio Pharma (Suzhou) Co  (HKSE:01779) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Longbio Pharma (Suzhou) Co's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2024 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-175.562 * ( 1 - 0% )/( (110.593 + 107.072)/ 2 )
=-175.562/108.8325
=-161.31 %

where

Invested Capital(Q: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=158.986 - 17.785 - ( 116.066 - max(0, 101.145 - 131.753+116.066))
=110.593

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=251.388 - 13.27 - ( 211.16 - max(0, 92.19 - 223.236+211.16))
=107.072

Note: The Operating Income data used here is one times the annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Longbio Pharma (Suzhou) Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2024  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-175.347/( ( (19.365 + max(-40.689, 0)) + (15.784 + max(-40.309, 0)) )/ 2 )
=-175.347/( ( 19.365 + 15.784 )/ 2 )
=-175.347/17.5745
=-997.74 %

where Working Capital is:

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 15.624) - (17.785 + 0 + 38.528)
=-40.689

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 10.864) - (13.27 + 0 + 37.903)
=-40.309

When net working capital is negative, 0 is used.

Note: The EBIT data used here is one times the annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Longbio Pharma (Suzhou) Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=/11486.253
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Longbio Pharma (Suzhou) Co EBIT Related Terms

Longbio Pharma (Suzhou) Co EBIT Historical Data

* Premium members only.

The historical data trend for Longbio Pharma (Suzhou) Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Longbio Pharma (Suzhou) Co EBIT Chart

Longbio Pharma (Suzhou) Co Annual Data
Trend Dec24 Dec25
EBIT
-113.52 -175.35

Longbio Pharma (Suzhou) Co Semi-Annual Data
Dec24 Dec25
EBIT -113.52 -175.35

HKSE:01779 vs : EBIT Comparison

For the Biotechnology subindustry, Longbio Pharma (Suzhou) Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Longbio Pharma (Suzhou) Co EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Longbio Pharma (Suzhou) Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Longbio Pharma (Suzhou) Co's EV-to-EBIT falls into.


HKSE:01779
10GF Score
Longbio Pharma (Suzhou) Co Ltd HKSE:01779
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Longbio Pharma (Suzhou) Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was HK$ Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of HK$ Mil mean?
Longbio Pharma (Suzhou) Co (HKSE:01779) has a EBIT of HK$ Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Longbio Pharma (Suzhou) Co.
Is Longbio Pharma (Suzhou) Co's EBIT too high?
Longbio Pharma (Suzhou) Co's current EBIT is HK$ Mil. Overall, Longbio Pharma (Suzhou) Co has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Longbio Pharma (Suzhou) Co's EBIT compare to ?
Longbio Pharma (Suzhou) Co's EBIT of HK$ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Longbio Pharma (Suzhou) Co. Longbio Pharma (Suzhou) Co's current EBIT is HK$ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Longbio Pharma (Suzhou) Co stock overvalued right now?
Longbio Pharma (Suzhou) Co (HKSE:01779) has a current EBIT of HK$ Mil. The current EBIT is HK$ Mil. Longbio Pharma (Suzhou) Co's overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Longbio Pharma (Suzhou) Co (HKSE:01779), the current EBIT is HK$ Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Longbio Pharma (Suzhou) Co Business Description

Comparable Companies
Address No. 128 Yinhe Road, Dongnan Subdistrict, 5th Floor, Building F, Area A, Changshu City, Jiangsu Province, Suzhou, CHN
Longbio Pharma (Suzhou) Co Ltd is a clinical-stage biotechnology company. The company and its subsidiaries are principally engaged in the research, development, manufacture and commercialisation of pharmaceutical products in the People's Republic of China (the PRC). It has developed a comprehensive product pipeline for biologic treatments targeting rhinology, dermatology, respiratory, hematology, nephrology and other autoimmune diseases, targeting allergic and autoimmune diseases. Its pipeline includes LP-003, LP-00A, LP-005, LP-00C, and LP-00D.
10GF Score

Get the complete analysis for HKSE:01779

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$150.00
Price